Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene

Br J Haematol. 2021 Feb;192(4):e112-e115. doi: 10.1111/bjh.17340. Epub 2021 Jan 27.

Authors

Yannick Wouters^{1

2}, Louis Nevejan³, Annelies Louwagie², Helena Devos³, Barbara Dewaele⁴, Dominik Selleslag⁵, Lucienne Michaux⁴

Affiliations

¹ Department of Laboratory Medicine, Sint-Franciscus Hospital, Heusden-Zolder, Belgium.
² Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
³ Department of Laboratory Medicine, AZ Sint-Jan Hospital Brugge-Oostende, Bruges, Belgium.
⁴ Center for Human Genetics, University Hospitals Leuven and KU Leuven, Leuven, Belgium.
⁵ Department of Hematology, AZ Sint-Jan Hospital Brugge-Oostende, Bruges, Belgium.

PMID: 33502001
DOI: 10.1111/bjh.17340

No abstract available

Keywords: PCM1; PCM1-JAK2; B-ALL; ruxolitinib; t(8;9).

Publication types

Case Reports
Letter

MeSH terms

Aged
Female
Humans
Janus Kinase Inhibitors / therapeutic use*
Nitriles
Oncogene Proteins, Fusion / genetics*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology
Pyrazoles / therapeutic use*
Pyrimidines
Treatment Outcome

Substances

Janus Kinase Inhibitors
Nitriles
Oncogene Proteins, Fusion
PCM1-JAK2 fusion protein, human
Pyrazoles
Pyrimidines
ruxolitinib